Skip to main content
Hengrui Pharma logo

Hengrui Pharma — Investor Relations & Filings

Ticker · 600276 ISIN · CNE0000014W7 LEI · 2549003BT1XS3SE3E448 HKEX Manufacturing
Open in API
Filings indexed 2,702 across all filing types
Latest filing 2026-04-16 Declaration of Voting R…
Country CN China
Listing HKEX 600276

About Hengrui Pharma

https://www.hrs.com

Hengrui Pharma is an innovative, global pharmaceutical company focused on the research, development, manufacturing, and commercialization of medicines. The company specializes in therapies for oncology, surgical applications, and interventional imaging. With a strong commitment to R&D, Hengrui has developed and commercialized numerous new molecular entities and is expanding its portfolio to address unmet medical needs in international markets. Its core activities revolve around creating high-quality and accessible treatments, particularly in the field of cancer therapy.

Recent filings

Filing Released Lang Actions
恒瑞医药2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document is a detailed announcement of the resolutions passed at the 2025 Annual General Meeting (AGM) of Jiangsu Hengrui Medicine Co., Ltd. It includes voting results on various proposals such as the annual report, profit distribution, board elections, and governance amendments. The document also contains information about the meeting's attendance, voting procedures, and legal opinions confirming the meeting's compliance with relevant laws and regulations. The content is focused on the shareholder meeting decisions and voting outcomes rather than the full annual report itself. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is sufficient and contains detailed voting data, confirming it is not a mere announcement of a report publication but the actual voting results from the AGM.
2026-04-16 Chinese
恒瑞医药第十届董事会第一次会议决议公告
Board/Management Information Classification · 100% confidence The document is an announcement of the resolutions passed at the first meeting of the 10th Board of Directors of Jiangsu Hengrui Medicine Co., Ltd. It details the election of the chairman, vice chairman, committee members, and appointments of senior management positions such as president, CFO, and board secretary. The document includes voting results and biographical information of the appointed executives. There are no financial statements or detailed financial performance data. The content focuses on board and management changes, which fits the category of Board/Management Information (MANG). The document length is 4272 characters, which is consistent with a detailed announcement but not a full report like an annual or interim report.
2026-04-16 Chinese
恒瑞医药关于药物纳入突破性治疗品种名单的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by Jiangsu Hengrui Medicine Co., Ltd. regarding the inclusion of a drug (SHR-A2102) in the breakthrough therapy designation list by the National Medical Products Administration's Center for Drug Evaluation. It details the drug's basic information, clinical background, and risk warnings. The document is a formal public announcement about regulatory status and drug development progress, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial data. The document length is short (1781 characters) and it serves as a regulatory announcement about drug status. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-04-16 Chinese
恒瑞医药2025年年度股东会法律意见书
AGM Information Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2025 Annual General Meeting (AGM) of Jiangsu Hengrui Medicine Co., Ltd. It details the legality and validity of the AGM's convening, attendance, voting procedures, and results. The document does not contain financial statements or detailed financial performance data but focuses on the procedural and legal aspects of the AGM. It is not the AGM materials or presentations themselves but a legal opinion related to the AGM. Therefore, it fits best under the category of AGM Information (AGM-R), which includes presentations and materials shared during the AGM or related official documents about the AGM process.
2026-04-16 Chinese
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
Governance Information Classification · 84% confidence The document is a standalone announcement detailing the company’s board composition and committee structure (executive, non-executive, and independent directors, plus audit, remuneration, nomination and strategy committees) with roles and terms of reference. There are no appointment or resignation notices (i.e. no changes or vote results), and it focuses on governance structure rather than financial results or regulatory filings. This fits the definition of a Governance Information report (CGR).
2026-04-16 English
(1) POLL RESULTS OF THE 2025 ANNUAL GENERAL MEETING (2) DISTRIBUTION OF CASH DIVIDEND (3) APPOINTMENT OF DIRECTORS OF THE TENTH SESSION OF THE BOARD (4) RETIREMENT OF INDEPENDENT NON-EXECUTIVE DIRECTO
Declaration of Voting Results & Voting Rights Announcements Classification · 83% confidence The document is an announcement issued after the company’s Annual General Meeting, detailing the poll results for each resolution (vote counts for ordinary and special resolutions) along with ensuing actions such as dividend distribution, board appointments and retirements. The core of the filing is the formal declaration of voting outcomes at the AGM. This aligns directly with the “Declaration of Voting Results & Voting Rights Announcements” category (DVA).
2026-04-16 English

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.